创新药“隐形王者”，低市值+外资疯抢+华为唯一认证，比舒泰神更正宗！

Group 1 - The innovation drug sector is currently experiencing significant attention and growth, with a warning against chasing high-priced stocks like Lianhua Technology and Shutaishen, which have seen substantial price increases [1][5] - 2023 has been a year of explosive new drug approvals, with a notable event on May 29 when the National Medical Products Administration issued 11 new drug approvals, with five coming from innovative drug companies on the Sci-Tech Innovation Board [3][4] - The innovation drug sector has shown a continuous growth trend for seven weeks, breaking through the historical resistance level of 1180 points, indicating strong upward momentum and potential [5] Group 2 - Investors are advised to focus on small-cap stocks that are severely undervalued and possess core technologies, as larger companies with market caps in the hundreds of billions may offer limited profit potential [7] - Notable small-cap stocks include: - Saiseng Pharmaceutical, with a market cap of approximately 6.5 billion yuan, focusing on nerve repair and immune regulation, with a key product being the first domestic nerve glycoside approved for clinical efficacy [9] - Anglikang, with a market cap of around 5.2 billion yuan, transitioning towards tumor microenvironment activation therapies, with several innovative drugs in clinical trials [10] - A third company, referred to as an "invisible king," is developing a long-acting therapeutic vaccine for cardiovascular treatment, with a market cap of less than 3 billion yuan and significant interest from foreign investment firms [11]